The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $22.30

Today's change0.00 0.00%
Updated January 23 4:01 PM EST. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $22.30

Today's change0.00 0.00%
Updated January 23 4:01 PM EST. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc closed at (U.S.)$22.30.

Shares have lost 2.96% for the last five days, but have gained 59.40% over the last 52 weeks. This security has outperformed the S&P 500 by 34.88% during the last year.

Key company metrics

  • Open(U.S.) $22.18
  • Previous close(U.S.) $22.30
  • High(U.S.) $22.86
  • Low(U.S.) $22.18
  • Bid / Ask-- / --
  • YTD % change+7.31%
  • Volume8,550,879
  • Average volume (10-day)12,167,649
  • Average volume (1-month)19,529,066
  • Average volume (3-month)15,497,694
  • 52-week range(U.S.) $8.31 to (U.S.) $24.43
  • Beta-0.24
  • Trailing P/E5.71×
  • P/E 1 year forward5.85×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $3.90
Updated January 23 4:01 PM EST. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2017Q2/2017Q1/2017Q4/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201709/30/2017Jun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016
Revenue2,2192,2332,1092,403
Total other revenue--------
Total revenue2,2192,2332,1092,403
Gross profit1,5601,5871,5131,737
Total cost of revenue659646596665
Total operating expense2,1822,0581,9622,252
Selling / general / administrative623659661665
Research & development81949693
Depreciation / amortization657623635284
Interest expense (income), net operating--------
Unusual expense (income)16238-27453
Other operating expenses, total0-2193
Operating income37175147150
Interest income (expense), net non-operating-459-459-474-467
Gain (loss) on sale of assets--------
Other--------
Income before tax-400-242-295-360
Income after tax1,300-37629-512
Income tax, total-1,700-205-924152
Net income1,301-38628-515
Total adjustments to net income--------
Net income before extra. items1,301-38628-515
Minority interest1-1-1-3
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1,301-38628-515
Inc. avail. to common incl. extra. items1,301-38628-515
Diluted net income1,301-38628-515
Dilution adjustment0------
Diluted weighted average shares352350351350
Diluted EPS excluding extraordinary itemsvalue per share3.69-0.111.79-1.47
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share3.99-0.041.75-0.65